Clinical diagnosis, treatment and preventive measures of non-alcoholic fatty liver disease-associated hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-3232.2026.05.021

Abstract

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is an important risk factor for hepatocellular carcinoma (HCC), and its global prevalence is rising rapidly. With the change of lifestyle and control of viral hepatitis, NAFLD is gradually becoming the primary cause of HCC. HCC is closely associated with chronic liver disease and has become an important cause of cancer-related death worldwide. Therefore, early intervention and monitoring of NAFLD patients and timely diagnosis of HCC patients play a significant role. In this article, clinical diagnosis, treatment and preventive measures of NAFLD-related HCC were systematically reviewed.

Key words: Non-alcoholic fatty liver disease(NAFLD), Carcinoma,hepatocellular, Treatment, Protective measure

Hongnian Shen, Hanxiao Lu, Shuo Zhang, Jie Xiang, Jun Yang. Clinical diagnosis, treatment and preventive measures of non-alcoholic fatty liver disease-associated hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2026, 15(05): 831-837.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2026.05.021

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2026/V15/I05/831

References 64

[1]	Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84.DOI: 10.1002/hep.28431.
[2]	Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.DOI: 10.1016/S2468-1253(19)30039-1.
[3]	Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4): 896-904.DOI: 10.1016/j.jhep.2018.05.036.
[4]	Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691.DOI: 10.1001/jamaoncol.2017.3055.
[5]	Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.DOI: 10.1038/s41575-019-0186-y.
[6]	Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2019, 5(12): 1749-1768.DOI: 10.1001/jamaoncol.2019.2996.
[7]	Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238.DOI: 10.1038/s41575-020-00381-6.
[8]	Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133.DOI: 10.1002/hep.30702.
[9]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.DOI: 10.3322/caac.21492.
[10]	Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62(6): 1723-1730.DOI: 10.1002/hep.28123.
[11]	Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study[J]. Hepatology, 2016, 63(3): 827-838.DOI: 10.1002/hep.28368.
[12]	Phipps M, Livanos A, Guo A, et al. Gender matters: characteristics of hepatocellular carcinoma in women from a large, multicenter study in the United States[J]. Am J Gastroenterol, 2020, 115(9): 1486-1495.DOI: 10.14309/ajg.0000000000000643.
[13]	Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases[J]. Aliment Pharmacol Ther, 2018, 48(7): 696-703.DOI: 10.1111/apt.14937.
[14]	Desai A, Sandhu S, Lai JP, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review[J]. World J Hepatol, 2019, 11(1): 1-18.DOI: 10.4254/wjh.v11.i1.1.
[15]	Hagström H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1. 2 million men[J]. Gut, 2018, 67(8): 1536-1542.DOI: 10.1136/gutjnl-2016-313622.
[16]	Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts[J]. BMC Med, 2019, 17(1): 95.DOI: 10.1186/s12916-019-1321-x.
[17]	Raff EJ, Kakati D, Bloomer JR, et al. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases[J]. J Clin Transl Hepatol, 2015, 3(1): 9-16.DOI: 10.14218/JCTH.2015.00001.
[18]	Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71(3): 907-916.DOI: 10.1002/hep.30858.
[19]	Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71(3): 808-819.DOI: 10.1002/hep.31014.
[20]	Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis[J]. PLoS Med, 2014, 11(4): e1001624.DOI: 10.1371/journal.pmed.1001624.
[21]	Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2018, 68(2): 723-750.DOI: 10.1002/hep.29913.
[22]	Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.DOI: 10.1016/j.jhep.2018.03.019.
[23]	Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis[J]. Gastroenterology, 2018, 154(6): 1706-1718. e1.DOI: 10.1053/j.gastro.2018.01.064.
[24]	Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2017, 45(1): 169-177.DOI: 10.1111/apt.13841.
[25]	Jin L, Min L, Sung L, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis[J]. Radiology, 2015, 275(1): 97-109.DOI: 10.1148/radiol.14140690.
[26]	Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 401-421.DOI: 10.1002/hep.29487.
[27]	Terzi E, Ayuso C, Piscaglia F, et al. Liver imaging reporting and data system: review of pros and cons[J]. Semin Liver Dis, 2022, 42(1): 104-111.DOI: 10.1055/s-0041-1732356.
[28]	Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv238-iv255.DOI: 10.1093/annonc/mdy308.
[29]	Calderaro J, Ziol M, Paradis V, et al. Molecular and histological correlations in liver cancer[J]. J Hepatol, 2019, 71(3): 616-630.DOI: 10.1016/j.jhep.2019.06.001.
[30]	Torbenson MS. Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes[J]. Hum Pathol, 2021, 112: 86-101.DOI: 10.1016/j.humpath.2020.12.009.
[31]	Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients[J]. Clin Gastroenterol Hepatol, 2016, 14(6): 875-886. e6.DOI: 10.1016/j.cgh.2015.12.042.
[32]	Parikh ND, Mehta AS, Singal AG, et al. Biomarkers for the early detection of hepatocellular carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(12): 2495-2503.DOI: 10.1158/1055-9965.EPI-20-0005.
[33]	Guan MC, Zhang SY, Ding Q, et al. The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases: a systematic review and meta-analysis[J]. J Clin Med, 2023, 12(3): 949.DOI: 10.3390/jcm12030949.
[34]	Lehrich BM, Zhang J, Monga SP, et al. Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma[J]. J Hepatol, 2024, 80(3): 515-530.DOI: 10.1016/j.jhep.2023.11.030.
[35]	Angeli-Pahim I, Chambers A, Duarte S, et al. Current trends in surgical management of hepatocellular carcinoma[J]. Cancers, 2023, 15(22): 5378.DOI: 10.3390/cancers15225378.
[36]	Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606.DOI: 10.1016/j.jhep.2022.08.021.
[37]	Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76(3): 681-693.DOI: 10.1016/j.jhep.2021.11.018.
[38]	Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma[J]. Gastroenterology, 2005, 129(1): 122-130.DOI: 10.1053/j.gastro.2005.04.009.
[39]	Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase Ⅲ randomised controlled trial[J]. Gut, 2017, 66(6): 1172-1173.DOI: 10.1136/gutjnl-2016-312629.
[40]	Xu Z, Hall TL, Vlaisavljevich E, et al. Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound[J]. Int J Hyperthermia, 2021, 38(1): 561-575.DOI: 10.1080/02656736.2021.1905189.
[41]	Wah TM, Pech M, Thormann M, et al. A multi-centre, single arm, non-randomized, prospective European trial to evaluate the safety and efficacy of the HistoSonics system in the treatment of primary and metastatic liver cancers (#HOPE4LIVER)[J]. Cardiovasc Intervent Radiol, 2023, 46(2): 259-267.DOI: 10.1007/s00270-022-03309-6.
[42]	Mendiratta-Lala M, Wiggermann P, Pech M, et al. The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors[J]. Radiology, 2024, 312(3): e233051.DOI: 10.1148/radiol.233051.
[43]	Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study[J]. Cardiovasc Intervent Radiol, 2010, 33(1): 41-52.DOI: 10.1007/s00270-009-9711-7.
[44]	Young B, Yoo JJ, Won J, et al. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization[J]. Korean J Intern Med, 2019, 34(6): 1223-1232.DOI: 10.3904/kjim.2018.058.
[45]	Lau WY, Teoh YL, Win KM, et al. Current role of selective internal radiation with yttrium-90 in liver tumors[J]. Future Oncol, 2016, 12(9): 1193-1204.DOI: 10.2217/fon-2016-0035.
[46]	Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-64.DOI: 10.1053/j.gastro.2009.09.006.
[47]	Duran R, Deltenre P, Denys A. RE: Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2017, 152(6): 1625-1626.DOI: 10.1053/j.gastro.2016.09.069.
[48]	Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(13): 3843-3849.DOI: 10.3748/wjg.v21.i13.3843.
[49]	Muñoz-Martínez S, Iserte G, Sanduzzi-Zamparelli M, et al. Current pharmacological treatment of hepatocellular carcinoma[J]. Curr Opin Pharmacol, 2021, 60: 141-148.DOI: 10.1016/j.coph.2021.07.009.
[50]	Foerster F, Gairing SJ, Ilyas SI, et al. Emerging immunotherapy for HCC: a guide for hepatologists[J]. Hepatology, 2022, 75(6): 1604-1626.DOI: 10.1002/hep.32447.
[51]	Gong XL, Qin SK. Progress in systemic therapy of advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(29): 6582-6594.DOI: 10.3748/wjg.v22.i29.6582.
[52]	Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention[J]. J Hepatol, 2021, 75(5): 1217-1227.DOI: 10.1016/j.jhep.2021.07.025.
[53]	Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis[J]. Hepatology, 2010, 51(1): 121-129.DOI: 10.1002/hep.23276.
[54]	Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes[J]. Diabetes Care, 2010, 33(10): 2156-2163.DOI: 10.2337/dc10-0856.
[55]	Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149(2): 367-378. e5; quiz e14-e15.DOI: 10.1053/j.gastro.2015.04.005.
[56]	Tamura T, Wada K, Konishi K, et al. Coffee, green tea, and caffeine intake and liver cancer risk: a prospective cohort study[J]. Nutr Cancer, 2018, 70(8): 1210-1216.DOI: 10.1080/01635581.2018.1512638.
[57]	Longo M, Meroni M, Paolini E, et al. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?[J]. Metabolism, 2021, 117: 154708.DOI: 10.1016/j.metabol.2021.154708.
[58]	Petrick JL, Campbell PT, Koshiol J, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project[J]. Br J Cancer, 2018, 118(7): 1005-1012.DOI: 10.1038/s41416-018-0007-z.
[59]	El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence[J]. Clin Gastroenterol Hepatol, 2006, 4(3): 369-380.DOI: 10.1016/j.cgh.2005.12.007.
[60]	Papadakos SP, Ferraro D, Carbone G, et al. The emerging role of metformin in the treatment of hepatocellular carcinoma: is there any value in repurposing metformin for HCC immunotherapy?[J]. Cancers, 2023, 15(12): 3161.DOI: 10.3390/cancers15123161.
[61]	Harati R, Vandamme M, Blanchet B, et al. Drug-drug interaction between metformin and sorafenib alters antitumor effect in hepatocellular carcinoma cells[J]. Mol Pharmacol, 2021, 100(1): 32-45.DOI: 10.1124/molpharm.120.000223.
[62]	Simon TG, Duberg AS, Aleman S, et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality[J]. N Engl J Med, 2020, 382(11): 1018-1028.DOI: 10.1056/NEJMoa1912035.
[63]	Simon TG, Henson J, Osganian S, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2019, 17(13): 2776-2784. e4.DOI: 10.1016/j.cgh.2019.04.061.
[64]	Foderà D, D’Alessandro N, Cusimano A, et al. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors[J]. Ann N Y Acad Sci, 2004, 1028: 440-449.DOI: 10.1196/annals.1322.052.

Please choose a citation manager

Content to export